Marta Barisa

Solid tumour immunotherapy @ UCL
Great Ormond Street Hospital for Children, London, UK

[UCLH @uclh]

Patients with an aggressive form of leukaemia will now be able to receive a breakthrough immunotherapy on the NHS which was developed and trialled at UCLH and UCL.

Find out more: https://t.co/EE5BeQX7Wt

[Chris Tape @christophertape]

Excited to share our new paper: ‘Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation’ led by @CallumNattress in collab. with Jonathan Fisher lab (1/13)
https://t.co/MB5pYMsAHT

[UCLH @uclh]

Today marks 20 years since University College Hospital opened.

Our CEO @probert_david said: “It stands as an example of how great architecture and planning can create a hospital that’s truly fit for purpose, helping our brilliant staff to provide the best care for our patients.”

[UCLH @uclh]

If you are pregnant, you are now eligible to receive a seasonal flu vaccine.

Getting vaccinated during pregnancy helps to protect both you and your baby.

Speak with your maternity team or GP to arrange an appointment.
https://t.co/5bM3h28zNZ

[Marta Barisa @MartaBarisa]

👩‍🔬 Check out the stunning AI-analysed videos of aB7H3 CAR-T killing clumps of patient-derived neuroblastoma generated by our colleagues @prinsesmaximac

🔬 CD4 CAR (blue), CD8 CAR (green), live tumours (yellow), dead tumours (red)
Full story https://t.co/MpIQtb497O @NatureComms

[Marta Barisa @MartaBarisa]

3of3

🔬 Consequently, only high avidity CAR-T both killed targets and proliferated, enabling long-term responses

[Marta Barisa @MartaBarisa]

🚨 Avidity of clinical-stage aB7H3 scFv CAR-T's predicts function 🚨

The conclusions took us by surprise, in the opposite direction of canonically held knowledge about CD19- CARs in leukaemia

Check out our latest story in @NatureComms
https://t.co/MpIQtb497O

[Marta Barisa @MartaBarisa]

2of3

🔬 High avidity was required to engage IL-2 production and proliferation, but not necessarily cytotoxicity

[Waggoner Lab @LabWaggoner]

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for antigen-dim cell targeting & avoidance of antigen-dim tumor relapse
@MartaBarisa @NatureComms
https://t.co/CJZJFVg9yO

[Cell Therapy News @celltherapynews]

Researchers led by Drs. @MartaBarisa, Judith Wienke, and John Anderson find that functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function.

📖 Learn more: https://t.co/oaGFr3feuv

[Samuel Hume @DrSamuelBHume]

Super interesting – and now supported by evidence from a randomized trial

Blue: each day's chemo-immunotherapy was started and completed before 3 pm

Red: each day's therapy was started and completed after 3 pm

Those who received treatment early in the day had better survival

[Cancer Grand Challenges @CancerGrand]

Today, @BarzilayRegina’s group @MIT released Boltz-2.

With accuracy rivalling AlphaFold3, the updated model can now predict small molecule-protein binding affinity.

Crucially, Boltz-2 is open source.

Read more: https://t.co/7GWzOs4U1N

[Population, Policy and Practice Department @ich_ppp]

A 3-year PhD Studentship in environmental child health research, epidemiology and statistics is available at @ich_ppp @UCLchildhealth @ucl from October 2025 supervised by Prof Pia Hardelid & Dr Niloofar Shoari

See https://t.co/mj6IRZQxHD
Closing Date30-Jun-2025

[Marta Barisa @MartaBarisa]

@VitanzaNick @US_FDA Congratulations on this beautiful work!

[Marta Barisa @MartaBarisa]

🌟 I’ve written a kid’s book about vaccines-the greatest ever paediatric health innovation.

I struggled to find resources to explain this to my son that were accessible to him, so I wrote my own.
Everyone is welcome to our story time! 🔬

Find it here: https://t.co/yl3t80hpQ7.

[Waggoner Lab @LabWaggoner]

Review @NatureBiotech @romeerizwan et al
Engineering innate immune cells for cancer immunotherapy
https://t.co/i3tw2wSoiH

[Rizwan Romee @romeerizwan]

Excited to share our review on CAR arming of the innate immune cells. Engineering innate immune cells for cancer immunotherapy | Nature Biotechnology https://t.co/MCUbnycSXL